- Stocks
- Pharma & Healthcare
- Mangalam Drugs And Organics
Mangalam Drugs And Organics share price
NSE: MANGALAMPharma & HealthcareDrug Manufacturers - Specialty & Generic
Mangalam Drugs And Organics at a glance
Mangalam Drugs And Organics (NSE: MANGALAM) closed at ₹29.66 on 22 Oct 2026, down 3.07% on the day. With a market capitalisation of ₹47 Cr, it ranks 3106th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was −43.1% in FY26. Over the past year the share price has fallen 58.5%. Its 52-week range is ₹22.80 (29 Dec 2025) to ₹71.99 (23 Oct 2025); the last close is 58.8% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹67 Cr (−7.5% year on year) and net profit −₹13 Cr (−22,466.7%), on a consolidated basis. Promoters held 35.65% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹47 CrRank 3106 on NSE
- Price to book
- 0.43×FY26
- EPS (TTM)
- −₹28.05to Q4 FY26
- ROE
- −43.1%FY26
- ROCE
- −27.3%FY26
- Debt to equity
- 1.02FY26
- Net profit margin
- −19.1%FY26
- Book value / share
- ₹65.11FY26
- 52-week high
- ₹71.9923 Oct 2025
- 52-week low
- ₹22.8029 Dec 2025
- 1-year return
- −58.5%
- RSI (14-day)
- 43.2
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −3.07% | −9.6% | −9.6% | +8.8% | −58.5% |
Mangalam Drugs And Organics quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹76 Cr | ₹80 Cr | ₹89 Cr | ₹73 Cr | ₹57 Cr | ₹49 Cr | ₹58 Cr | ₹67 Cr |
| Revenue YoY | — | — | −9.0% | −28.6% | −25.2% | −38.4% | −34.1% | −7.5% |
| Net profit | ₹3 Cr | ₹3 Cr | ₹1 Cr | ₹0 Cr | −₹14 Cr | −₹7 Cr | −₹10 Cr | −₹13 Cr |
| Net profit YoY | — | — | +158.0% | −98.3% | −614.9% | −373.2% | −862.8% | −22,466.7% |
| Net margin | 3.5% | 3.4% | 1.5% | 0.1% | −24.1% | −14.9% | −16.9% | −19.9% |
| EPS | ₹1.70 | ₹1.70 | ₹0.81 | ₹0.04 | −₹8.72 | −₹4.64 | −₹6.21 | −₹8.48 |
Mangalam Drugs And Organics financials
| Item | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹369 Cr | ₹318 Cr | — |
| Operating profit | −₹11 Cr | ₹5 Cr | — |
| Net profit | −₹9 Cr | ₹7 Cr | — |
| EPS (₹) | −₹6.00 | ₹4.00 | — |
| Cash from operations | ₹4 Cr | ₹43 Cr | — |
| Total debt | ₹13 Cr | ₹9 Cr | ₹9 Cr |
| Shareholders' equity | ₹136 Cr | ₹149 Cr | ₹103 Cr |
Mangalam Drugs And Organics shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 50.30% | 50.30% | 50.30% | 35.64% | 35.65% | 35.65% |
| Foreign institutions | 0.47% | 0.53% | 0.11% | 0.13% | 0.32% | 0.11% |
| Domestic institutions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Non-institutions | 49.23% | 49.16% | 49.58% | 64.22% | 64.02% | 64.24% |
Mangalam Drugs And Organics vs peers
The listed Pharma & Healthcare companies nearest to Mangalam Drugs And Organics by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SHREEPACShree Pacetroni | — | — | — | ₹50 Cr | — | — |
| BIOFILCHEMBiofil Chemicals & Pharmaceuticals | ₹30.00 | +2.15% | −27.3% | ₹49 Cr | 17.5 | — |
| SHANMUGAShanmuga Hospit | — | — | — | ₹48 Cr | — | — |
| MANGALAMMangalam Drugs And Organics | ₹29.66 | −3.07% | −58.5% | ₹47 Cr | — | — |
| AMKAYAmkay Products | — | — | — | ₹46 Cr | — | — |
| SHELTERShelter Pharma | — | — | — | ₹46 Cr | — | — |
| VISTAPHVista Pharma | — | — | — | ₹45 Cr | — | — |
Ask anything about Mangalam Drugs And Organics
Pivot answers on the live chart with evidence you can check, and tests strategies against MANGALAM's own history. Try: “Why has MANGALAM moved over the last three months?” · “Backtest a 50-day moving-average crossover on MANGALAM over five years” · “Compare MANGALAM with SHREEPAC on margins and valuation”
Frequently asked questions about Mangalam Drugs And Organics
What is the share price of Mangalam Drugs And Organics today?
Mangalam Drugs And Organics (NSE: MANGALAM) last closed at ₹29.66 on 22 Oct 2026. Its 52-week high is ₹71.99 and its 52-week low is ₹22.80.
What is the market cap of Mangalam Drugs And Organics?
Mangalam Drugs And Organics' market capitalisation is ₹47 Cr (₹47 Cr) at the 22 Oct 2026 close, ranking 3106th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Mangalam Drugs And Organics?
Return on equity was −43.1% in FY26 and return on capital employed was −27.3% in FY26 (consolidated figures).
Is Mangalam Drugs And Organics a debt-free company?
No. Mangalam Drugs And Organics' debt-to-equity ratio was 1.02 in FY26, with total debt of ₹9 Cr.
What were Mangalam Drugs And Organics' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Mangalam Drugs And Organics reported revenue of ₹67 Cr, −7.5% year on year, and net profit of −₹13 Cr, −22,466.7% year on year.
How has Mangalam Drugs And Organics stock performed over the last year?
Mangalam Drugs And Organics' share price has fallen 58.5% over the past year, +8.8% over three months and −9.6% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Mangalam Drugs And Organics?
As of 30 Jun 2026: promoters 35.65%, foreign institutions 0.11%, domestic institutions 0.00%, non-institutions 64.24%.
Who are Mangalam Drugs And Organics' competitors?
The listed Pharma & Healthcare companies closest to Mangalam Drugs And Organics by market cap are Shree Pacetroni, Biofil Chemicals & Pharmaceuticals, Shanmuga Hospit, Amkay Products, Shelter Pharma and Vista Pharma.
Is Mangalam Drugs And Organics a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Mangalam Drugs And Organics' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MANGALAM against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with M · all NSE stocks · this page as text